Polaryx Therapeutics, Inc. Segments Disclosure
6. Segment Information
The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company’s costs associated with the preclinical and clinical development of the Company’s product candidates. The Company currently is in the clinical stage and manages its business activities on an aggregate basis.
The accounting policies of the lysosomal storage disorders segment are consistent with those described in Note 2, Summary of Significant Accounting Policies, and the measure of segment assets is reported on the balance sheets as total assets. The Company’s CODM is the . The CODM assesses performance of the lysosomal storage disorders segment using operating expenses as reported in the statements of operations and comprehensive loss. Operating expenses is assessed by the CODM to make decisions on how to allocate resources, such as determining additional costs for preclinical and clinical development of the Company’s product candidates.
The following table summarized significant segment expenses for the years ended December 31, 2025 and 2024:
| Lysosomal Storage Disorders Segment | ||||||||
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| (In thousands) | ||||||||
| Research and development expenses (excluding stock compensation) | $ | (1,922 | ) | $ | (1,077 | ) | ||
| General and administrative expenses (excluding stock compensation) | (1,174 | ) | (875 | ) | ||||
| Stock-based compensation | (4,725 | ) | (2,400 | ) | ||||
| Recapitalization of common stock | (26,004 | ) | ||||||
| Other expense – direct listing offering costs | (1,164 | ) | ||||||
| Net loss | $ | (8,985 | ) | $ | (30,356 | ) | ||
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.